concentration is above the minimum inhibitory concentration (MIC) of the bacteria. 9-11 Continuous infusion administration can achieve time above the MIC for the entire dosing interval, which may be critical for the treatment of multidrug-resistant P. aeruginosa. Intermittent dosing may allow drug concentrations to fall below the MIC of the resistant organism, which would permit bacterial survival and regrowth.
As more infections caused by resistant P. aeruginosa are encountered, continuous infusion antimicrobial strategies may achieve successful outcomes and diminish the probability of breakthrough infections. However, to our knowledge, there are few reported cases and no case series in the available literature that document continuous infusion βlactam antibiotic therapy against these infections. The objective of this case series is to describe our use of continuous infusion β-lactam antibiotics for the treatment of resistant P. aeruginosa infections in immunocompromised inpatients at the National Institutes of Health Clinical Center. This case series describes a unique strategy, using highdose continuous infusion ceftazidime or aztreonam to target high drug concentrations at or above the MIC for the treatment of resistant P. aeruginosa infections.
Case Reports
Continuous infusion ceftazidime in 2 immunocompromised patients and aztreonam in a third such patient were used for the treatment of P. aeruginosa bacteremia, pneumonia, and serious wound infections (Tables 1 and 2) . Formulas used to calculate the dosage regimens are shown in Appendix I. [12] [13] [14] [15] The case histories of these patients are summarized below.
CASE 1
An 18-year-old female with a history of a poorly characterized primary immunodeficiency, disseminated molluscum contagiosum, and disseminated herpes simplex virus infection developed aggressive cutaneous T-cell lymphoma/ leukemia. After finishing the second cycle of EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) chemotherapy (9/12-9/16), the patient became febrile and had blood cultures positive for P. aeruginosa (9/17 neous lesions associated with lymphoma and viral infections. Cultures of these cutaneous lesions grew P. aeruginosa.
Ciprofloxacin, trimethoprim/sulfamethoxazole, and tobramycin 200 mg (5 mg/kg) administered intravenously every 24 hours were added to the patient's antibiotic regimen on 9/18, which also included vancomycin and imipenem. The antibacterial susceptibility profile showed that the P. aeruginosa isolates were susceptible to to-
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The Annals of Pharmacotherapy I 2010 May, Volume 44 I 931 theannals.com Table 2) . P. aeruginosa isolates were resistant to imipenem and ciprofloxacin in this patient. In order to more effectively treat this life-threatening bacteremia, ciprofloxacin, imipenem, and trimethoprim/sulfamethoxazole were discontinued; tobramycin was continued; and continuous infusion ceftazidime was initiated on 9/19 (loading dose 2 g, maintenance infusion rate 271 mg/h) to target a mean steady-state concentration (C ss ) of 64 mg/L. Neutropenia following chemotherapy lasted 5 days and resolved with filgrastim therapy. As the P. aeruginosa MIC of ceftazidime was found to be 64 mg/L, the maintenance infusion rate of ceftazidime was increased to 400 mg/h (9.6 g/day) on 9/22 to target a C ss of 80-100 mg/L. Within 6 days of initiation of continuous infusion ceftazidime, results of repeated blood cultures became negative (Table 1 ). During neutropenia from 9/19 to 9/22, blood cultures remained negative, but they became positive again on 9/23 while the patient was neutropenic and remained so during recovery from neutropenia on 9/24. Results of blood cultures again became negative with continuous infusion ceftazidime and recovery from neutropenia. Unfortunately, the patient's lymphoma failed to respond to the chemotherapy and she was given comfort care and died on 10/1. Postmortem cultures of the lung and liver were negative for P. aeruginosa.
CASE 2
A 17-year-old male with leukocyte adhesion deficiency type 1, nonhealing cutaneous ulcers on the thighs and scrotum, failed skin grafts, and multidrug-resistant P. aeruginosa wound infections developed bilateral pneumonia on 11/23. While the patient was receiving broad-spectrum antibiotics, P. aeruginosa and Mycobacterium intracellulare (1 colony) were recovered from a bronchoalveolar lavage on 11/24. P. aeruginosa also was recovered from thigh wound cultures on 11/23 and 11/25. The antibacterial susceptibility profile showed that the P. aeruginosa isolates were susceptible to polymyxin B and intermediate or resistant to all other antibiotics ( Table 2 ). Based on a previously successful response of the nonhealing ulcers to continuous infusion aztreonam, this infusion was reinitiated at 260 mg/h on 11/26. Traditional dosing of tobramycin was changed to intravenous tobramycin 270 mg (5 mg/kg) every 24 hours, and ciprofloxacin (11/19-12/1) and vancomycin were also continued. In addition, nebulized colistin (11/26-12/13), intravenous polymyxin B (11/26-12/1), and azithromycin were initiated for resistant or atypical pneumonia. Donor granulocyte infusions were started on 11/27 and continued until 7/16. After only 1 day of continuous infusion, aztreonam was held and then resumed on 12/1 at 350 mg/h (8.4 g/day) and continued for more than 8 months thereafter. The only concomitant medication active against P. aeruginosa during this time was nebulized colistin for 13 days. The wounds responded to continuous infusion aztreonam with multiple negative cultures over 8 months.
After the wounds were substantially reduced in size and P. aeruginosa was eradicated from the wounds, the patient was referred for plastic surgery, where he received multiple cultured epidermal autograft (Epicel, Genzyme Corp., Cambridge, MA) skin grafts. Continuous infusion aztreonam 350 mg/h, intermittently dosed tobramycin (to which the organism was resistant), and vancomycin were continued until 8/17. Continuous infusion aztreonam was well tolerated throughout the 8-month course of treatment. The patient was discharged on 8/23 with healed skin grafts.
CASE 3
A 44-year-old male with severe aplastic anemia associated with profound neutropenia developed recurrent P. aeruginosa infections, which were treated with several cycles of high-dose continuous infusion ceftazidime over 2 months while he was awaiting an unrelated cord blood transplant. Intermittently dosed ceftazidime was initially administered for fever and sinusitis; P. aeruginosa was recovered from sinus biopsy cultures on 1/20. The fever and sinusitis responded to ceftazidime; however, P. aeruginosa pneumonia was subsequently documented by bronchoalveolar lavage on 2/3. Meropenem was administered from 2/1 to 2/13 but was followed by fever, hypotension, and P. aeruginosa bacteremia on 2/15. Other P. aeruginosa-related events at this time included thyroiditis and myositis. The organism at this time was susceptible to ceftazidime (MIC ≤8 mg/L) but resistant to aztreonam, imipenem, and meropenem. In light of these recurrent infectious events, the rapid emergence of resistance to carbapenems, and increasing MICs of the organism, intermittently dosed ceftazidime was changed to continuous infusion ceftazidime 700 mg/h (16.8 g/day), with a target concentration of 64-100 mg/L, on 2/19 to control infection and prevent further emergence of resistance. Intravenous ciprofloxacin 400 mg every 12 hours was administered concomitantly with continuous infusion ceftazidime. After blood cultures cleared during continuous infusion ceftazidime treatment, the dosing regimen was changed to 2 g intravenously every 8 hours on 2/25. Both ceftazidime and ciprofloxacin were discontinued on 3/1 but resumed on 3/10. On 3/10 the patient again developed fever and P. aeruginosa bacteremia. The isolate was susceptible to ceftazidime (MIC ≤8 mg/L) and ciprofloxacin (MIC ≤1 mg/L), intermediate to levofloxacin, and resistant to aztreonam and meropenem. Given the patient's previous response to continuous infusion administration, ceftazidime was restarted at 700 mg/h (16.8 g/day) from 3/11 to 3/14. New pulmonary infiltrates and pleuritic chest pain, which were thought to be caused by recurrent P. aeruginosa, 932 I The Annals of Pharmacotherapy I 2010 May, Volume 44 theannals.com prompted a change to ceftazidime 2 g infused every 8 hours from 3/14 to 3/18 and then to continuous infusion ceftazidime 417 mg/h (10 g/day) on 3/18. The ceftazidime infusion rate was decreased to 375 mg/h (9 g/day) on 3/21 in response to a decline in the patient's renal function (Table 1) . On 3/25, the patient developed facial fasciculation and the ceftazidime infusion rate was further decreased to 292 mg/h (7 g/day). The twitching resolved after dose reduction. The patient's bacteremia cleared and pneumonia improved while he received continuous infusion ceftazidime, which was discontinued on 4/29. During administration of antithymocyte globulin conditioning for an unrelated cord blood transplant, the patient developed fever, tachycardia, and chest pain and required intubation for diffuse pulmonary edema and pleural effusions. Following transplant conditioning, 2 unrelated donor cord blood units were infused on 5/5. Before neutrophil recovery could occur, ceftazidime-resistant P. aeruginosa bacteremia, pneumonia, ventriculitis, and choroid plexitis developed and became refractory to antimicrobial therapy. These events coincided with recovery of P. aeruginosa with ceftazidime MIC >16 mg/L from tracheal aspirate on 5/2 and blood on 5/8 ( Table 1 ). In response to this deterioration, imipenem, colistin, and aminoglycoside were administered. The patient died on 6/1 and postmortem cultures of the brain and lung grew P. aeruginosa.
Discussion
In vitro and in vivo studies, limited clinical data, and basic principles of continuous infusion β-lactam antibiotic therapy against P. aeruginosa were recently reviewed elsewhere and are summarized throughout this discussion. 14 Few clinical studies have been published on continuous infusion β-lactam antibiotics for the treatment of serious infections caused by P. aeruginosa. These studies are largely limited to respiratory infections in cystic fibrosis and cutaneous lesions in neutropenic hosts. [16] [17] [18] [19] [20] [21] Clinical studies using continuous infusion β-lactam antibiotics for the treatment of serious multidrug-resistant P. aeruginosa infections are even more limited. 22, 23 This report describes in detail high-dose continuous infusion β-lactam antibiotics for the treatment of resistant systemic P. aeruginosa infections in 3 chronically immunocompromised patients. The rationale for high-dose continuous infusion β-lactam antibiotics in such compromised patients is to provide sustained bactericidal concentrations above the MIC and to prevent emergence of resistance until the infection is resolved or the immune impairment (eg, profound neutropenia) is reversed. The rationale for use of ceftazidime in cases 1 and 3 is based on several factors: its well-established use as monotherapy in neutropenic patients, its safety profile, and/or its favorable MICs. The rationale for use of aztreonam in case 2 is based on a previously successful response in management of the nonhealing ulcers and an initial MIC of 16 mg/L.
In the first case, continuous infusion ceftazidime (target drug concentration ≥1.5 times MIC) was used to successfully treat multidrug-resistant P. aeruginosa bacteremia in a patient with primary immunodeficiency, neutropenia, and aggressive cutaneous T-cell lymphoma/leukemia. In the second case, continuous infusion aztreonam was used to successfully treat multidrug-resistant P. aeruginosa wound infections and pneumonia in a patient with leukocyte adhesion deficiency type 1. In the third case, continuous infusion ceftazidime (target drug concentration ≥4 times MIC) was used to treat P. aeruginosa pneumonia and bacteremia in a patient with severe aplastic anemia. In each case, the bacteremia cleared, infected wounds healed, and pneumonia improved in response to continuous infusion ceftazidime or aztreonam.
We believe that the concomitant use of tobramycin in cases 1 and 2 and ciprofloxacin in case 3 was ancillary in the treatment of P. aeruginosa infections in these profoundly compromised patients. Neither tobramycin nor ciprofloxacin is recommended as monotherapy in persistently neutropenic patients. 24 Among the in vitro and in vivo studies of continuous infusion β-lactam antibiotics for the treatment of P. aeruginosa, several reports suggest that maximum bactericidal activity occurs when drug levels are 4-5 times the MIC. [25] [26] [27] [28] In vitro and in vivo studies also suggest that β-lactam antibiotic drug concentrations 2 times the MIC may be bactericidal against some strains of P. aeruginosa. 29, 30 While drug concentrations 4 -5 times the MIC are optimal, this may not be safely achievable in all patients. Given the elevated MIC of 64 mg/L for ceftazidime in the first patient, a target maximum C ss of 100 mg/L (1.5 times MIC) was approximated. Although higher concentrations (4 times MIC) of ceftazidime would have been preferable, these concentrations could not be administered due to potential neurotoxicity. A similar situation occurred in the second patient. The MIC of aztreonam was 96 mg/L and, for other β-lactam antibiotics, the MICs were off-scale. Aztreonam was administered at an infusion rate to approximate this MIC in order to avoid neurotoxicity. In comparison, the third patient demonstrated that targeting a C ss of ≥4 times the MIC was feasible when the MIC was 8 mg/L. Thus, factors of both efficacy and toxicity should be considered when calculating a dosage for continuous infusion β-lactam antibiotics.
Neurotoxicity is one of the most serious potential adverse effects of β-lactam antibiotics and may include confusion, disorientation, somnolence, twitching, myoclonus, and seizures. 31 Risk factors for neurotoxicity include high dosages, history of seizures, other central nervous system disorders, renal failure, and concomitant drugs that lower the seizure threshold. 31, 32 Our third patient developed facial fasci-
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This case series describes a continuous infusion β-lactam antibiotic dosing strategy for the treatment of resistant P. aeruginosa infections in immunocompromised patients when antibiotic options are limited. Loading doses and maintenance infusion rates should be calculated as described in Appendix I. A more detailed description of these calculations has been recently published. 14 Total daily doses of continuous infusion β-lactam antibiotics are traditionally less than or equal to their intermittent infusion regimens. However, our approach in targeting high drug concentrations is unique in that it results in higher total daily doses of ceftazidime or aztreonam compared with those resulting from intermittent administration. Nonetheless, in order to prevent neurotoxicity, the maximum recommended drug concentration of ceftazidime or aztreonam is 100 mg/L; this concentration is based on our clinical experience and review of the literature. 14 The limitations of this case series are the small number of patients, the absence of drug concentrations, and use of combination therapy for the treatment of P. aeruginosa infections. Assays for determination of concentrations of ceftazidime and aztreonam were not available within our institution. However, the case series described herein is unique in that it demonstrates that high-dose continuous infusion β-lactam antibiotic therapy is feasible in immunocompromised patients, it may be useful in managing multidrug-resistant P. aeruginosa infections, and it may improve outcome.
In conclusion, this report demonstrates that high-dose continuous infusion β-lactam antibiotics are a potentially useful treatment strategy for resistant P. aeruginosa infections in critically ill immunocompromised patients. While this approach is not a panacea for treatment of multidrugresistant P. aeruginosa infections, it may provide an addi-tional treatment option when antibiotic choices are limited. This report also may provide a conceptual framework for prospective clinical studies to determine the safety and efficacy of high-dose continuous infusion β-lactam antibiotics in immunocompromised hosts. 
